Discussing Cartilage Regeneration

An interview from the Scientist: "Cartilage is a firm, yet elastic, connective tissue that cushions joints and minimizes friction between bones. It is made up mostly of a matrix of collagen and proteoglycans and lacks nerve cells or blood vessels. In fact, cartilage contains only one cell type, the chondrocyte. A joint injury is often followed by progressive degeneration of cartilage, but there is hope that stem cells injected into damaged cartilage can help repair it. University Hospital Basel tissue engineer Ivan Martin discusses a recent study that sheds light on the mysterious process of cartilage regeneration by tracking labeled, implanted cells using a conventional MRI scanner ... [For treating cartilage injury] there is a very promising, relatively new technique - the use of autologous cartilage cells, or chondrocytes, which are expanded ex vivo and injected into the defective area. Even more recently, people have considered using mesenchymal stem cells, which are the progenitors of chondrocytes. ... We cannot just continue injecting cells and looking two years down the road to see if there is a change or not in the clinical results. We need to have control over the treatment we apply in order to understand the mechanisms of action and to be able to predict with better reproducibility the clinical outcome. This [MRI-based] technique would possibly contribute or provide the technical means to address this important scientific question."

Link: http://the-scientist.com/2011/05/30/cellular-salve/

Confusion Abounds, Especially When Religion and Spirituality Become Involved

Confusion is an important barrier to overcome when advocating engineered human longevity. For those folk who are not paying much attention to the topic - which is, sadly, 99.9% of the present roster of the human race - there's little apparent difference between advocacy for real, plausible scientific development and the nonsense of the "anti-aging" marketplace. It's pretty much all the same to them, and that's a big problem.

One of the long term projects for the advocacy community is to raise the general level of education and awareness, such that a far greater number of people do know that they should support SENS research and not the ramblings of the pill and potion vendors if they do have an interest in living longer. Not a small project, but we can all help.

Things become somewhat worse when we pull in religions and spirituality, however. To go along with the confusion created by the prodigious and often duplicitous output of "anti-aging" salespeople, there are entire armies of people who place immortality in the spiritual sense into the same bucket as life extension through science. They are even more confused - and you can find a good example in a recent article that shifts seamlessly between radical life extension through technology, the longevity of being famous, and Buddhist spirituality. All in the same category for that author.

Religious believes are, unfortunately, delusions. It's just the same as any dream of lazy immortality - such as the possibility that you are software in a simulation, a brain in a jar, or one of infinitely many copies in a universe of many parallel worlds. You shouldn't live your life banking on being a brain in a jar, and you shouldn't live your life banking on a supernatural continuation of your existence post-mortem. All that these comfortable beliefs give you is the chance to feel good while failing to achieve the material, real-world goals that will give you a greater chance at a far longer life. It's grand failure, while pretending to succeed.

While it's tempting to let the religious have their cozy refuge, that's no way to run a campaign of advocacy for scientific development, as noted at length by other authors:

As far as every experiment ever done is concerned, [the Dirac] equation is the correct description of how electrons behave at everyday energies. ... If you believe in an immaterial soul that interacts with our bodies, you need to believe that this equation is not right, even at everyday energies. There needs to be a new term (at minimum) on the right, representing how the soul interacts with electrons. (If that term doesn't exist, electrons will just go on their way as if there weren't any soul at all, and then what's the point?) So any respectable scientist who took this idea seriously would be asking - what form does that interaction take?

...

Nobody ever asks these questions out loud, possibly because of how silly they sound. Once you start asking them, the choice you are faced with becomes clear: either overthrow everything we think we have learned about modern physics, or distrust the stew of religious accounts/unreliable testimony/wishful thinking that makes people believe in the possibility of life after death. It's not a difficult decision, as scientific theory-choice goes.

We don't choose theories in a vacuum. We are allowed - indeed, required - to ask how claims about how the world works fit in with other things we know about how the world works. ... There's no reason to be agnostic about ideas that are dramatically incompatible with everything we know about modern science. Once we get over any reluctance to face reality on this issue, we can get down to the much more interesting questions of how human beings and consciousness really work.

The same goes for engineering longer lives for ourselves and our descendants. That worthy goal is fundamentally undermined by the widespread acceptance of supernatural immortality. The religious nature of your average human and human society is yet another hurdle to overcome - it won't be going away any time soon, given its origin in evolved human nature, but we have to find good ways to work around its effects.

Artificial Hearts Without Heartbeats

The interesting question regarding the removal of the human heartbeat is the impact it will have on other bodily systems. Will it extend life by reducing stress on, for example, vulnerable blood vessels in the brain, or will it shorten life by also eliminating the beneficial response to that stress? Researchers are making progress in artificial hearts, so this question will likely be answered at some point over the next few decades: "The search for the perfect artificial heart seems never-ending. After decades of trial and error, surgeons remain stymied in their quest for a machine that does not wear out, break down or cause clots and infections. But Dr. Billy Cohn and Dr. Bud Frazier at the Texas Heart Institute say they have developed a machine that could avoid all that with simple whirling rotors - which means people may soon get a heart that has no beat. Inside the institute's animal research laboratory is an 8-month-old calf with a soft brown coat named Abigail. Cohn and Frazier removed Abigail's heart and replaced it with two centrifugal pumps. ... If you listened to her chest with a stethoscope, you wouldn't hear a heartbeat. If you examined her arteries, there's no pulse. If you hooked her up to an EKG, she'd be flat-lined. ... The pumps spin Abigail's blood and move it through her body. ... The doctors say the continuous-flow pump should last longer than other artificial hearts and cause fewer problems. That's because each side has just one moving part: the constantly whirling rotor. But Cohn says they will still have to convince the world that you don't need a pulse to live. ... We look at all the animals, insects, fish, reptiles and certainly all mammals, and see a pulsatile circulation. And so all the early research and all the early efforts were directed at making pulsatile pumps. ... However, the only reason blood must be pumped rhythmically instead of continuously is the heart tissue itself. ... The pulsatility of the flow is essential for the heart, because it can only get nourishment in between heartbeats. If you remove that from the system, none of the other organs seem to care much."

Link: http://www.npr.org/2011/06/13/137029208/heart-with-no-beat-offers-hope-of-new-lease-on-life

Investigating the Graying of Hair

If the level of interest the public has in their gray hair could only be transferred to an interest in practical work to repair aging, how much better off we'd be. Here is more research into the biological causes of loss of hair pigmentation with aging: "Wnt signaling, already known to control many biological processes, between hair follicles and melanocyte stem cells can dictate hair pigmentation. ... We have known for decades that hair follicle stem cells and pigment-producing melanocycte cells collaborate to produce colored hair, but the underlying reasons were unknown. We discovered Wnt signaling is essential for coordinated actions of these two stem cell lineages and critical for hair pigmentation. ... The study suggests the manipulation of Wnt signaling may be a novel strategy for targeting pigmentation such as graying hair. The research study also illustrates a model for tissue regeneration. ... Using genetic mouse models, researchers were able to examine how Wnt signaling pathways enabled both hair follicle stem cells and melanocyte stem cells to work together to generate hair growth and produce hair color. Research also showed the depletion (or inhibition or abnormal) Wnt signaling in hair follicle stem cells not only inhibits hair re-growth but also prevents melanocytes stem cell activation required for producing hair color. The lack of Wnt activation in melanocyte stem cells leads to depigmented or gray hair."

Link: http://www.sciencedaily.com/releases/2011/06/110614115046.htm

Should We Treat Aging?

"Should we treat aging?" is a rhetorical question here, but sadly it remains a straightforward open question for much of the world - when it is asked, they are quite serious in asking it. People expect there to be good reasons as to why aging should be left as it is, the cause of death for more than 100,000 people each and every day, and scientists restrained from working on therapies of rejuvenation. This is one of the uphill struggles taking place in the patient advocacy community for aging research, that most people don't consider themselves patients exhibiting the symptoms of degenerative aging, have little inclination to do anything about it, and are in fact initially hostile to the whole idea.

Here's an American Scientist article from researcher David Gems that asks the rhetorical question in the title of this post, and answers it for those who don't see things the way we do:

I am a scientist working in the growing field of biogerontology - the biology of aging. The cause of aging remains one of the great unsolved scientific mysteries. Still, the past decade has brought real progress in our understanding, raising the prospect that treatments might one day be feasible. Yet aging is not just another disease. And the prospect of treating aging is extraordinary in terms of the potential impact on the human condition. So, would it be ethical to try to treat it?

...

I argue for the recognition of an imperative to seek treatments that decelerate aging in order to alleviate late-life diseases. But at what point would such an imperative be fulfilled? Although decelerating aging would postpone the illnesses of aging, it would not make them any less awful. This means that achieving decelerated aging would not lessen the imperative. We would only be compelled to decelerate aging further, and then further still. Here the ethical calculus seems to set us inexorably on a road to ever-greater life extension. Could any sane authority ever opt to force others to forego treatment and suffer from avoidable age-related disease? Surely not.

So it is that decelerated aging would force a dilemma upon us. Should we alleviate suffering on a large scale and accept life extension? Or should we allow an immensity of avoidable suffering in order to avoid extending life? To my mind, the only reasonable course is the first. In fact, we should pursue it energetically, and begin to prevent illness as soon as is feasible. If not, we risk the fury of future generations for dithering. As for life extension, we will just have to take that on the chin. If we can prepare for it socially, politically and institutionally, and if we keep birth rates low, we should be able to ensure long, healthier, happier lives for our children and for our children's children.

In reading this, one must understand there there are a great many people in the world whose first, instinctive reaction to extending healthy human life is to reject it. For them, life extension is indeed a bad thing. Various strains of environmentalism are one of the main culprits here: so many minds are poisoned by the false ideas that spread from environmentalist and related Malthusian ideologies: that there are too many people, that people are intrinsically bad, that wealth and longevity are intrinsically bad, that economics is a zero-sum game, and so forth.

There's nothing wrong with liking trees and wild places enough to spend your hard-earned resources on helping to maintain them. But environmentalism has a way of veering off into the worship of death and destruction, a sort of modern penitent movement focused on the mortification of society as a whole. It's so widespread and embedded in our cultures now that even mild-mannered, everyday folk declare their support for shorter and fewer human lives, for abandonment of technologies that improve the quality of human life, and for relinquishment of technological development that will greatly improve life in the future.

In the long run, these are the ideas we must defeat and bury if we are to build the level of understanding and support required to speed the advent of rejuvenation biotechnology.

Meat industry lying about E. coli contamination

The meat industry has been misusing data to make it appear that E. coli contamination of meat is decreasing, said Barbara Kowalcyk of the Center for Foodborne Illness, Research and Prevention.

Executives from the American Meat Institute (AMI) have claimed success in the beef industry's efforts to reduce contamination with the dangerous E. coli strain O157:H7. According to the AMI, inspection data from the U.S. Department of Agriculture's (USDA's) Food Safety and Inspection Service show a 45 percent drop in E. coli prevalence between 2000 and 2008.

Yet Kowalcyk calls this is a misuse of data never intended for "year-to-year comparisons."

"USDA's E. coli ... testing program is strictly regulatory and was not statistically designed to estimate the prevalence of E. coli O157:H7 in raw ground beef," she said.

Although a 45 percent drop is in fact found in the data, Kowalcyk notes that different facilities were tested and different testing methods used each year. She called the AMI's conclusion as valid as comparing a person who weighed 300 pounds in 2000 to a different person weighing 150 pounds in 2008, then concluding that the average weight of the U.S. population had dropped 50 percent. Read more...

Ayurtox for Body Detoxification

A New Look at Obsessive-Compulsive Disorder (preview)

One day 12-year-old Elizabeth McIngvale became obsessed with the number 42, which happened to be her mother’s age at the time, 11 years ago. When she washed her hands, she had to turn the sink on and off 42 times, get 42 pumps of soap and rinse her hands 42 times. Sometimes she decided that she actually needed to do 42 sets of 42. When she dressed, she put her right leg in and out of her pant leg 42 times, then the left. Even getting up from a chair took 42 attempts. She was afraid that if she did not follow her self-prescribed ritual, something terrible would happen to her family--they might die in a car accident, for instance. “Everything I did was completely exhausting and grueling,” she recalls. “I was probably doing 12 to 13 hours a day of rituals.”

McIngvale was diagnosed with obsessive- compulsive disorder (OCD), a psychiatric illness that afflicts 2 to 3 percent of Americans, not all of them as severely as McIngvale. Individuals with OCD experience debilitating recurrent and persistent thoughts, or obsessions, which they try to suppress or eliminate with rituals, known as compulsions. Compared with people who have other anxiety or mood disorders, adults with OCD are more likely to be single and unemployed. In fact, OCD is among the 10 most disabling medical and psychiatric conditions.

[More]

Add to digg
Add to StumbleUpon
Add to Reddit
Add to Facebook
Add to del.icio.us
Email this Article


Autism's Tangled Genetics Full of Rare and Varied Mutations

The underpinnings of autism are turning out to be even more varied than the disease's diverse manifestations. In four new studies and an analysis published June 8 researchers have added some major landmarks in the complex landscape of the disease, uncovering clues as to why the disease is so much more prevalent in male children and how such varied genetic mutations can lead to similar symptoms. [More]

Add to digg
Add to StumbleUpon
Add to Reddit
Add to Facebook
Add to del.icio.us
Email this Article


Autism’s Tangled Genetics Full of Rare and Varied Mutations

The underpinnings of autism are turning out to be even more varied than the disease's diverse manifestations. In four new studies and an analysis published June 8 researchers have added some major landmarks in the complex landscape of the disease, uncovering clues as to why the disease is so much more prevalent in male children and how such varied genetic mutations can lead to similar symptoms. [More]

Add to digg
Add to StumbleUpon
Add to Reddit
Add to Facebook
Add to del.icio.us
Email this Article


International Stem Cell Corporation (ISCO) Announces That Donna Queen, Former President and CEO of ZO SKIN HEALTH, the Luxury Brand Created by Zein Obagi, MD, Has Joined ISCO Executive Team

International Stem Cell Corporation (OTCBB:ISCOE) announced today that Donna Queen has joined ISCO's executive team. Ms. Queen will be primarily responsible for ISCO's wholly owned subsidiary Lifeline Skin Care's (Lifeline) brand identity and international marketing as well as broadening the range of Lifeline products currently available.


Prior to joining ISCO, Ms. Queen was President and CEO of ZO SKIN HEALTH® by Zein Obagi, MD. Dr. Obagi is the dermatologist who created the original Obagi Nu-Derm skincare system, which has since become the leading physician-dispensed brand of anti-aging skincare. Earlier Ms. Queen founded and led one of Virginia's largest advertising and marketing agencies, specializing in aesthetic and dermatological marketing and brand development.


Dr. Andrey Semechkin, President and CEO of ISCO, commented: "I'm very pleased that Ms. Queen has joined our team. Ms. Queen's industry experience and expertise particularly in marketing prescription-based products will be invaluable as we expand our skin care business and further enhance our line of products."


Ms. Queen adds, "I'm very excited to be joining such a dynamic, science-driven company. There have been no recent meaningful technological breakthroughs in skin care, but with ISCO's scientific leadership in stem cells and their knowledge of skin tissue physiology we have an opportunity to continue to deliver new and innovative treatments."


ISCO previously announced sales of approximately $1.1 million from the pilot direct-to-consumer launch of Lifeline's first two products, an anti-aging Day Serum and a Night Serum. These products were developed by ISCO's scientific research team in collaboration with internationally recognized cosmetics experts. The serums contain an extract from ISCO?s proprietary human parthenogenetic stem cells combined with antioxidants and botanically derived ingredients. Using these serums on a regular basis provides significant benefits to the skin including improvement in skin tone and elasticity and the improvement in the appearance of fine lines and wrinkles, results that have been independently established by clinical studies performed at industry-leading testing laboratories. The serums can be purchased by visiting Lifeline?s website at http://www.lifelineskincare.com and are also available at selected luxury spas and physicians' offices in the United States.


About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.


To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.


Forward-looking Statements
Statements pertaining to anticipated developments, product development and marketing plans, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, competition, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.


http://cts.businesswire.com/ct/CT?id=bwnews&sty=20110616005464r1&sid=14230&distro=ftp
International Stem Cell Corporation
760-940-6383
Ruslan Semechkin, PhD
Vice President, ISCO
CEO, Lifeline Skin Care
ras@intlstemcell.com

or
Simon Craw, PhD
Vice President, ISCO
sc@intlstemcell.com
or
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com

International Stem Cell to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on June 16


International Stem Cell Corporation (OTCBB:ISCOE) announced today that Kenneth Aldrich, Chairman, will present to investors as part of the Lippert/Heilshorn & Associates Life Sciences & Medical Technologies Virtual Conference on Thursday, June 16, 2011 at 10:30 a.m. Eastern.

A webcast of the presentation will be accessible online at http://www.internationalstemcell.com, or the PrecisionIR event site: http://www.vcall.com/CustomEvent/lipper/index.aspAn archived version will be available for 30 days.

About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

International Stem Cell Corporation
Kenneth C Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com

or
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com

International Stem Cell to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on June 16


International Stem Cell Corporation (OTCBB:ISCOE) announced today that Kenneth Aldrich, Chairman, will present to investors as part of the Lippert/Heilshorn & Associates Life Sciences & Medical Technologies Virtual Conference on Thursday, June 16, 2011 at 10:30 a.m. Eastern.

A webcast of the presentation will be accessible online at http://www.internationalstemcell.com, or the PrecisionIR event site: http://www.vcall.com/CustomEvent/lipper/index.aspAn archived version will be available for 30 days.

About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

International Stem Cell Corporation
Kenneth C Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com

or
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com

Tricia's Story of Multiple Sclerosis

Update from Tricia September 17, 2008: Thank you all for your kind and encouraging words! When I hear how my story has touched people around the world, I can't believe it! When the National MS Society put together and posted the video, I was shocked at the response. Now, three years later, people are still watching it, forwarding it and commenting on it - wow! My son Jake will be 15 this year, he still loves playing baseball and is a freshman in High School

See the original post here:
Tricia's Story of Multiple Sclerosis

Tricia’s Story of Multiple Sclerosis

Update from Tricia September 17, 2008: Thank you all for your kind and encouraging words! When I hear how my story has touched people around the world, I can't believe it! When the National MS Society put together and posted the video, I was shocked at the response. Now, three years later, people are still watching it, forwarding it and commenting on it - wow! My son Jake will be 15 this year, he still loves playing baseball and is a freshman in High School

See the original post here:
Tricia's Story of Multiple Sclerosis